Iron and Parkinson’s disease

Neuroscientist

Volumn 8, Issue 1, 2002, Pages 22-32

  Wolozin, Benjamin ^a   Golts, Natalie ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Aggregation; Ferritin; Lactoferrin; Lewy body; Neuromelanin; Oxidation; Synuclein; Transferrin

Indexed keywords

ALPHA SYNUCLEIN; COMPLEMENTARY DNA; FERRITIN; IRON; IRON BINDING PROTEIN; IRON REGULATORY FACTOR; LACTOFERRIN; MAGNESIUM; MITOGEN ACTIVATED PROTEIN KINASE; NEUROMELANIN; PARKIN; PHOSPHOLIPASE C; PROTEIN 14 3 3; PROTEIN KINASE C; TAU PROTEIN; TRANSFERRIN;

BRAIN LEVEL; HUMAN; IRON STORAGE; IRON TRANSPORT; LEWY BODY; NONHUMAN; OXIDATION; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW; SUBSTANTIA NIGRA;

ALPHA-SYNUCLEIN; ANIMALS; HUMANS; IRON; NERVE TISSUE PROTEINS; PARKINSON DISEASE; SYNUCLEINS;

EID: 0036152892     PISSN: 10738584     EISSN: None     Source Type: Journal    
DOI: 10.1177/107385840200800107     Document Type: Review

References (56)

1. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system
2. Phosphorus magnetic resonance spectroscopy in multiple system atrophy and Parkinson’s disease
3. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease
4. The CYP2D6B allele is associated with a milder synaptic pathology in Alzheimer’s disease
5. Parkin is metabolized by the ubiquitin/proteosomal system
6. A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer’s diseased brains
7. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease
8. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation
9. Multiple system atrophy: A sporadic synucleinopathy
10. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions
11. Autoradiographic localization and density of [125I]ferrotransferrin binding sites in the basal ganglia of control subjects, patients with Parkinson’s disease and MPTP-lesioned monkeys
12. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease
13. A Drosophila model of Parkinson’s disease
14. Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology
15. Rat alpha-synuclein interacts with Tat binding protein 1, a component of the 26S proteasomal complex
16. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions
17. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly
18. Assessment of plasma lactoferrin in Parkinson’s disease
19. Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro
20. Role of cytochrome c as a stimulator of α-synuclein aggregation in Lewy body disease
21. Selective vulnerability of pigmented dopaminergic neurons in Parkinson’s disease
22. Nuclear translocation of NF-κ B is increased in dopaminergic neurons of patients with Parkinson disease
23. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer’s disease
24. Regulation of phospholipase D2: Selective inhibition of mammalian phospholipase D isoenzymes by α and β synucleins
25. Alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356
26. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson’s disease
27. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins
28. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein
29. Environmental risk factors and Parkinson’s disease: A case-control study in Taiwan
30. Altered systemic iron metabolism in Parkinson’s disease
31. Increased basal ganglia iron in striatonigral degeneration: In vivo estimation with magnetic resonance
32. Proteasomal function is impaired in substantia nigra in Parkinson’s disease
33. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons
34. Accelerated filament formation from tau protein with specific FTDP-17 missense mutations
35. The role of glutathione in dopaminergic neuronal survival
36. Alpha-synuclein immunoreactivity is present in axonal swellings in neuroaxonal dystrophy and acute traumatic brain injury
37. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity
38. α-synuclein shares physical and functional homology with 14-3-3 proteins
39. The A53T α-synuclein mutation increases iron-dependent aggregation and toxicity
40. Parkinson’s disease: A disorder due to nigral glutathione deficiency
41. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease
42. Function and regulation of transferrin and ferritin
43. The value of transgenic models for the study of neurodegenerative diseases
44. Synucleins are a novel class of substrates for G protein-coupled receptor kinases
45. Parkinson’s disease mortality and the industrial use of heavy metals in Michigan
46. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with formation of intranuclear inclusions
47. Parkinson’s disease and exposure to rural environmental factors: A population based case-control study
48. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer’s therapy
49. α-synuclein in Lewy bodies
50. Iron-regulatory proteins, iron-responsive elements and ferritin mRNA translation
51. Synphilin-1 is present in Lewy bodies in Parkinson’s disease
52. Mechanisms of neurodegenerative disorders. Part I: Protein aggregates
53. α-synuclein fibrillogenesis is nucleation-dependent: Implications for Parkinson’s disease
54. Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: Consequences for iron storage and neurodegenerative processes